Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
MYLAN Dec-18 |
ABBOTT INDIA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 3,561 | - | |
Low | Rs | 5,458 | 1,960 | - | |
Sales per share (Unadj.) | Rs | 1,731.1 | 1,638.8 | - | |
Earnings per share (Unadj.) | Rs | 211.9 | 44.5 | - | |
Cash flow per share (Unadj.) | Rs | 219.9 | 351.3 | - | |
Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
Dividend yield (eoy) | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 945.2 | 1,772.8 | - | |
Shares outstanding (eoy) | m | 21.25 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 1.7 | 245.0% | |
Avg P/E ratio | x | 33.7 | 62.0 | 54.3% | |
P/CF ratio (eoy) | x | 32.5 | 7.9 | 413.6% | |
Price / Book Value ratio | x | 7.6 | 1.6 | 485.5% | |
Dividend payout | % | 30.7 | 0 | - | |
Avg Mkt Cap | Rs m | 151,848 | 1,420,461 | 10.7% | |
No. of employees | `000 | 3.5 | 35.0 | 10.0% | |
Total wages/salary | Rs m | 4,356 | 0 | - | |
Avg. sales/employee | Rs Th | 10,555.5 | 24,089.9 | 43.8% | |
Avg. wages/employee | Rs Th | 1,249.9 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,292.2 | 654.1 | 197.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 843,147 | 4.4% | |
Other income | Rs m | 1,133 | 0 | - | |
Total revenues | Rs m | 37,919 | 843,147 | 4.5% | |
Gross profit | Rs m | 6,047 | 218,175 | 2.8% | |
Depreciation | Rs m | 169 | 157,870 | 0.1% | |
Interest | Rs m | 23 | 40,552 | 0.1% | |
Profit before tax | Rs m | 6,989 | 19,752 | 35.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,485 | -3,142 | -79.1% | |
Profit after tax | Rs m | 4,503 | 22,895 | 19.7% | |
Gross profit margin | % | 16.4 | 25.9 | 63.5% | |
Effective tax rate | % | 35.6 | -15.9 | -223.5% | |
Net profit margin | % | 12.2 | 2.7 | 450.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 470,812 | 5.9% | |
Current liabilities | Rs m | 8,569 | 343,274 | 2.5% | |
Net working cap to sales | % | 51.8 | 15.1 | 342.2% | |
Current ratio | x | 3.2 | 1.4 | 234.9% | |
Inventory Days | Days | 60 | 84 | 72.0% | |
Debtors Days | Days | 27 | 93 | 29.4% | |
Net fixed assets | Rs m | 1,057 | 163,557 | 0.6% | |
Share capital | Rs m | 213 | 449 | 47.3% | |
Net worth | Rs m | 20,086 | 912,131 | 2.2% | |
Long term debt | Rs m | 0 | 984,482 | 0.0% | |
Total assets | Rs m | 29,409 | 2,446,689 | 1.2% | |
Interest coverage | x | 311.6 | 1.5 | 20,953.7% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.3 | 363.0% | |
Return on assets | % | 15.4 | 2.6 | 593.4% | |
Return on equity | % | 22.4 | 2.5 | 893.2% | |
Return on capital | % | 34.9 | 3.2 | 1,097.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | 175,206 | 2.8% | |
From Investments | Rs m | -2,570 | -90,562 | 2.8% | |
From Financial Activity | Rs m | -1,428 | -81,621 | 1.7% | |
Net Cashflow | Rs m | 993 | 1,452 | 68.4% |
Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: DR. DATSONS LABS TORRENT PHARMA PANACEA BIOTECH VENUS REMEDIES BIOCON
Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
This could take India to the position of 3rd largest economy.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More